Chemi Homoeo Laboratory Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-07-2024
- Paid Up Capital ₹ 0.80 M
as on 09-07-2024
- Company Age 22 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 5.38 M
as on 09-07-2024
- Revenue -35.82%
(FY 2020)
- Profit 13.81%
(FY 2020)
- Ebitda -80.69%
(FY 2020)
- Net Worth -8.29%
(FY 2020)
- Total Assets 4.78%
(FY 2020)
About Chemi Homoeo Laboratory
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.80 M.
The company has closed loans amounting to ₹5.38 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Premendra Doshi and Nita Doshi serve as directors at the Company.
- CIN/LLPIN
U24234WB2002PTC094757
- Company No.
094757
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jun 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- LocationSonarpur, West Bengal
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Chemi Homoeo Laboratory Private Limited offer?
Chemi Homoeo Laboratory Private Limited offers a wide range of products and services, including Common Disease Medicines, Ointment, Homeopathic Medicines & Remedies, Homeopathic Drugs, Cough Syrup, Homeopathic Dilutions.
Who are the key members and board of directors at Chemi Homoeo Laboratory?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Premendra Doshi  | Director | 18-Jun-2002 | Current |
| Nita Doshi | Director | 24-Mar-2009 | Current |
Financial Performance of Chemi Homoeo Laboratory.
Chemi Homoeo Laboratory Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 35.82% decrease. The company also saw a substantial improvement in profitability, with a 13.81% increase in profit. The company's net worth dipped by a decrease of 8.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Chemi Homoeo Laboratory?
In 2020, Chemi Homoeo Laboratory had a promoter holding of 62.50% and a public holding of 37.50%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Uco Bank Creation Date: 16 Oct 2003 | ₹5.38 M | Satisfied |
How Many Employees Work at Chemi Homoeo Laboratory?
Unlock and access historical data on people associated with Chemi Homoeo Laboratory, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chemi Homoeo Laboratory, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chemi Homoeo Laboratory's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
